Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jeffrey Leiden, Anthony Shuber

Premium

Quest Diagnostics has elected Jeffrey Leiden to its Board of Directors. Leiden is the chairman, president, and CEO of Vertex Pharmaceuticals. Prior to that, he was a managing director at Clarus Ventures, and before that served as president, chief operating officer, and chief scientific officer at Abbott Laboratories. He has more than 20 years of scientific and commercial experience in the pharmaceutical and biotechnology industries as well as clinical and scientific experience as a cardiologist and molecular biologist.


Nabsys said that Anthony Shuber has joined the company as VP and chief scientific officer. He joins the firm from Ignyta, an oncology precision medicine firm, where he served as chief technology officer. Prior to joining Ignyta, Shuber was co-founder and CTO of Predictive Biosciences, and scientific co-founder of Exact Sciences. He also previously worked for Genzyme Genetics/Integrated Genetics and Genetics Institute.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.